Sotera Health Company $SHC Shares Purchased by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. increased its stake in Sotera Health Company by 5.9%, owning 8,045,502 shares valued at approximately $93.81 million.
• Sotera Health reported a quarterly earnings per share of $0.20, surpassing analysts' estimates, with a revenue of $294.34 million which was also above expectations.
• Several analysts have recently upgraded their ratings for Sotera Health, with Goldman Sachs raising its target price from $14.00 to $17.00 and maintaining a "buy" rating.

T. Rowe Price Investment Management Inc. increased its position in shares of Sotera Health Company (NASDAQ:SHC - Free Report) by 5.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,045,502 shares of the company's stock after acquiring an additional 450,761 shares during the quarter. T. Rowe Price Investment Management Inc. owned about 2.83% of Sotera Health worth $93,811,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of SHC. Sculptor Capital LP bought a new position in shares of Sotera Health during the 4th quarter worth approximately $68,400,000. Two Seas Capital LP raised its stake in shares of Sotera Health by 624.0% during the 4th quarter. Two Seas Capital LP now owns 2,896,136 shares of the company's stock worth $39,619,000 after acquiring an additional 2,496,136 shares in the last quarter. D. E. Shaw & Co. Inc. raised its stake in shares of Sotera Health by 140.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,624,750 shares of the company's stock worth $35,907,000 after acquiring an additional 1,534,666 shares in the last quarter. Ananym Capital Management LP bought a new position in shares of Sotera Health during the 4th quarter worth approximately $13,680,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Sotera Health by 27.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,143,955 shares of the company's stock worth $43,004,000 after acquiring an additional 673,979 shares in the last quarter. Institutional investors own 91.03% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. The Goldman Sachs Group upgraded shares of Sotera Health from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $14.00 to $17.00 in a research note on Monday, May 5th. Wall Street Zen raised shares of Sotera Health from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Finally, Barclays reissued an "overweight" rating on shares of Sotera Health in a research report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.00.

Sotera Health Price Performance

SHC traded up $0.50 on Friday, reaching $16.43. 1,302,737 shares of the company's stock were exchanged, compared to its average volume of 1,655,172. The stock has a market cap of $4.67 billion, a PE ratio of 205.40 and a beta of 1.81. Sotera Health Company has a twelve month low of $9.53 and a twelve month high of $17.08. The stock's fifty day moving average price is $12.35 and its 200-day moving average price is $12.16. The company has a debt-to-equity ratio of 4.49, a current ratio of 2.47 and a quick ratio of 2.23.

Sotera Health (NASDAQ:SHC - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.03. Sotera Health had a net margin of 2.14% and a return on equity of 39.42%. The firm had revenue of $294.34 million during the quarter, compared to analysts' expectations of $275.81 million. During the same period last year, the business earned $0.19 earnings per share. Sotera Health's revenue was up 6.4% compared to the same quarter last year. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. Sell-side analysts expect that Sotera Health Company will post 0.61 EPS for the current year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.